US · Healthcare · Biotechnology
EPS came in at -0.37 against a street estimate of -0.14 — a miss of 164.3%.
Analysts rate Travere Therapeutics Inc a strong buy (14 buy, 1 hold, 0 sell out of 15) with an average price target of $75.21.
CONFIDENT Travere delivered exceptional Q2 with FILSPARI revenue up 96% YoY to $141.1M. FSGS launch exceeded expectations with 2,000+ new patient starts. IgA nephropathy demand grew despite competition. Balance sheet strengthened via convertible refinancing. Q2 2026 No international breakdown provided; all revenue from U.S. operations. Analysts pressed on FSGS launch curve sustainability, conversion timelines, and competitive payer dynamics. Management emphasized breadth of early prescribing (70% from IgAN physicians, 30% new) as sign of durable demand, not bolus; highlighted superior payer access vs. IgAN launch and complementary role of combination therapies. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| HHG PLC | 12.11% |
| Jupiter Topco LLC | 12.01% |
| BlackRock Inc | 8.51% |
| FMR Inc | 7.53% |
| Bank of America Corp | 4.85% |
| State Street Corp | 4.52% |
| Vanguard Capital Management, LLC | 4.36% |
| Perceptive Advisors LLC | 3.98% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 TRAVERE THERAPEUTICS, INC. – FORM 8-K SUMMARY Report Date: September 21, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Leadership Transition Announced: | 2026-09-21 |
| Quarterly report · Q2 2026 TRAVERE THERAPEUTICS, INC. – FORM 10-Q SUMMARY Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and equivalents: $117.7 million (up from $93. | 2026-08-04 |
| Results announced · Q3 2026 TRAVERE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • U.S. net product sales Q2 2026: $161.4 million (vs. $94.8 million Q2 2025, | 2026-08-04 |
| Board / officer change · Q3 2026 TRAVERE THERAPEUTICS, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Travere Therapeutics, Inc. is a biopharmaceutical company incorporated | 2026-07-09 |
| Board / officer change · Q2 2026 TRAVERE THERAPEUTICS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • William Rote, Ph.D., Chief Research Officer, has announced his intenti | 2026-06-16 |
| Material agreement · Q2 2026 TRAVERE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Upfront payment to Everest Medicines: $112.5 million • Potential milestone payments: Up | 2026-06-02 |
| Quarterly report · Q1 2026 TRAVERE THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue: $127.2 million (Q1 2026) vs. $81.7 million (Q1 2025) – up 55.6% | 2026-05-04 |
| Proxy statement · Q2 2026 TRAVERE THERAPEUTICS, INC. — PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect ten director nominees to serve one-year terms • Propo | 2026-04-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Enters into license and collaboration agreement with Everest Medicines Travere Therapeutics entered into a license and collaboration agreement with Everest Medicines on June 1, 2026, to develop and commercialize civorebrutinib (EVER001), a BTK inhibitor drug ca | 2026-06-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Travere Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.